Wird geladen...
Cardioprotective diabetes drugs: what cardiologists need to know
In patients with diabetes, where cardiovascular morbidity is highly prevalent, recent cardiovascular outcomes trials have identified therapies in the modern glucagon-like peptide 1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) classes that significantly reduce card...
Gespeichert in:
| Veröffentlicht in: | Cardiovasc Endocrinol Metab |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wolters Kluwer Health
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6946151/ https://ncbi.nlm.nih.gov/pubmed/31942550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000181 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|